SecBot SecBot
S-3 ·Filed Nov 12, 2026

TCRT

Alaunos Therapeutics, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed4d 7h ago SEC0001193125-26-458953
Shelf registration (potential dilution)
Actionable Insight ▼ Bearish

Monitor the special meeting for stockholder approval of the conversion and authorized share increase. The massive overhang of 382M registrable shares (vs. 4.2M outstanding) will likely pressure the stock until conversion limitations and lockups expire. Watch for selling by Fairmount and other large holders post-conversion.

DirectionBearish
Confidencehigh
Horizonweeks

Drugs in focus

TCRT drug pipeline →

VLR199

● Neutral Named in this S-3
Impact
Phase
Preclinical / Early-stage
Time to market
Proof-of-concept data expected in 2028; any potential approval would be several years beyond that, if clinical trials succeed.
Next catalyst
None dated

What to watchVLR199 has no near-term binary catalyst; proof-of-concept data is not expected until 2028. The key near-term events for TCRT are the stockholder vote on preferred share conversion and the potential overhang from the 382M-share S-3 registration. The reverse merger transformed the company's financial position but at the cost of extreme dilution for legacy holders. Watch for clinical development updates on the Velaris PAH pipeline, but VLR199 is too early to drive a meaningful stock move in the next 12 months.

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$1.63
T+0 close · Nov 12, 2026 · via day close
Latest settled
−1.84%
T+1 · $1.60
Vs SPY
+0.07%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $1.63entry
  2. T+1 · 21h ago −1.84%α +0.07% · $1.60
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alaunos Therapeutics filed an S-3 shelf registration statement to register 382,090,789 shares of common stock for resale by selling stockholders, primarily in connection with the October 2026 reverse merger with Velaris Therapeutics and a concurrent $350 million PIPE financing. The shares include those issuable upon conversion of Series B and Series C preferred stock issued to former Velaris stockholders and PIPE investors. The company will not receive any proceeds from the resale.

Key Facts

  • S-3 registers 382,090,789 shares for resale by selling stockholders, representing massive potential dilution relative to 4,208,359 shares outstanding as of November 11, 2026
  • Shares include 105,286,000 shares issuable upon conversion of Series B preferred (Velaris merger consideration), 33,054,000 Series C merger shares, 687,789 PIPE common shares, and 243,063,000 PIPE conversion shares
  • Conversion of preferred shares requires stockholder approval (Conversion Approval and Authorized Share Increase); beneficial ownership limitations of 4.99% to 19.99% apply per holder
  • Company will not receive any proceeds from the resale; proceeds go entirely to selling stockholders
  • PIPE raised approximately $350 million at $1.4357 per share (common) and $1,435.70 per share of Series C preferred ($1.4357 per as-converted share)
  • Activist filings (SC 13D/A from WaterMill Asset Management and Fairmount Funds) within 28 days of this filing indicate activist pressure context
  • Fairmount Funds Management holds 174,937,789 shares (largest selling stockholder), with a 19.99% beneficial ownership limitation
  • Paragon Laboratories L.P. and Palaris Holding LLC each hold 13,161,000 shares with 4.99% beneficial ownership limitations
  • 180-day lockup applies to certain Velaris stockholders from the October 13, 2026 closing date
  • Registration fee calculated at $57,508.48 based on maximum aggregate offering price of $661,017,064.97

Financial Impact

Potential dilution of up to 382,090,789 shares vs. 4,208,359 shares outstanding (over 90x current shares), though subject to conversion approvals and beneficial ownership limits. PIPE raised $350 million at $1.4357/share.

dilutionshare countmarket cap

Risk Factors

  • Massive potential dilution: 382M shares registered vs. 4.2M outstanding, representing over 90x current share count if all converted and sold
  • Activist stakes (Fairmount 19.99%, WaterMill 9.99%) within 60 days of filing increase risk of forced selling or strategic pressure
  • Conversion requires stockholder approval; failure could delay or prevent conversion and create uncertainty
  • Company receives no proceeds from resale; capital raised in PIPE ($350M) already closed
  • Paragon Option Agreement includes reversion rights if company's stockholders equity falls below $200 million or if freely tradeable shares are not delivered within 120 days of warrant exercise

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
S-3 Filing (Primary)0001193125-26-458953
Document: d481859dex102.htm0001193125-26-458953
Document: d481859dex103.htm0001193125-26-458953
Document: d481859dexfilingfees.htm0001193125-26-458953
Document: d481859dex51.htm0001193125-26-458953
Document: d481859dex231.htm0001193125-26-458953
Document: 0001193125-26-458953-index-headers.html0001193125-26-458953

Track record

14 reports on TCRT

Performance horizon

2 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +26.36% at T+60 after the Apr 15, 2026 report. 3 of 8 went positive at some point.

Filters
  1. Nov 12, 20264d ago S-3 Bearish 6/10 Viewing Entry $1.63 Now $1.60 +1.84% settles Dec 14
  2. Oct 23, 202624d ago 8-K Bullish 5/10 Entry $2.13 Now $1.60 −24.88% settles Nov 23
  3. Oct 21, 202626d ago 8-K Bullish 7/10 Entry $3.04 Now $1.60 −47.37% settles Nov 19
  4. Oct 15, 20264w ago SC 13D/A Neutral 6/10 Entry $2.63 to $1.63 Now $1.60 −39.16% ▼ −38.02% −36.86% vs SPY
  5. Oct 15, 20264w ago SC 13D Neutral 5/10 Entry $2.63 to $1.63 Now $1.60 −39.16% ▼ −38.02% −36.86% vs SPY
  6. Oct 13, 20264w ago Press Release Bullish 8/10 Entry $3.03 to $1.67 Now $1.60 −47.19% ▼ −44.88% −41.21% vs SPY
  7. Oct 13, 20264w ago 8-K Bullish 8/10 Entry $3.03 to $1.71 Now $1.60 −47.19% ▼ −43.56% −39.95% vs SPY
  8. Oct 9, 20265w ago 8-K Bearish 7/10 Entry $1.05 to $1.67 Now $1.60 −52.38% ▼ −59.05% −62.31% vs SPY
  9. Sep 18, 20268w ago Press Release Bearish 5/10 Entry $1.20 to $2.63 Now $1.60 −33.33% ▼ −119.17% −118.96% vs SPY
  10. Sep 16, 20268w ago 8-K Neutral 2/10 Entry $1.60 to $2.18 Now $1.60 +0.00% ▲ +36.25% +34.79% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 5h 54m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026